Skip to content
Open access

CXCL9 drives lung adenocarcinoma progression and immunotherapy response via activation of the CXCR3/JAK1/STAT3 signaling pathway

Sep 2026 · Translational Oncology · Vol 73 · 1 citation · 58 references
Medicine

Abstract

Highlights • CXCL9 is upregulated in LUAD responders to PD-L1 immunotherapy.• High CXCL9 expression predicts poor prognosis in LUAD.• CXCL9 promotes LUAD cell proliferation, migration, and invasion.• CXCL9 activates CXCR3/JAK1/STAT3 signaling to drive malignancy.• JAK1/2 inhibitor Ruxolitinib reverses CXCL9-driven malignant phenotypes.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.